



PATENT

Attorney Docket No.: 5835.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgård-Frantzen et al

Serial No.: To Be Assigned ^{09/710,339}

Group Art Unit: To Be Assigned

Filed: November 9, 2000

Examiner: To Be Assigned

For: Fungamyl-like Alpha-Amylase Variants

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box DD
Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. PTO-1449 Form
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box DD
Commissioner for Patents
Washington, DC 20231

on November 16, 2000.

Kelley O'Patry
(name of person mailing paper)

K. O'Patry
(signature of person mailing paper)



Attorney Docket No.: 5835.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgård-Frantzen et al

Application No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: November 9, 2000

Examiner: To Be Assigned

For: Fungamyl-like Alpha-Amylase Variants

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed. The references are as follows:

1. WO 90/11352
2. WO 95/26397
3. WO 96/23873
4. WO 95/10603
5. WO 96/23874




It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of the application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b). Therefore, no fee is due.

Respectfully submitted,

Date: November 16, 2000



Jason I. Garbell, Reg. No. 44,116
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

FORM PTO-1449
(Rev. 2-32)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 5835.200-US

Serial No. To Be Assigned


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Applicant Bisgård-Frantzen et al

Filing Date November 9, 2000

Group To Be Assigned

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							TRANSLATION	
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
		WO 90/11352	10/90	WIPO				
		WO 95/26397	10/95	WIPO				
		WO 96/23873	8/96	WIPO				
		WO 95/10603	4/95	WIPO				
		WO 96/23874	8/96	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

EXAMINER

DATE CONSIDERED

				DATE CONSIDERED	
EXAMINER					
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					